Literature DB >> 1880731

A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling.

P Veng-Pedersen1, J W Mandema, M Danhof.   

Abstract

Many pharmacodynamic (PD) models may be generalized in the form E(t) = N(L[c(t)]), where E(t) is a recorded effect response, c(t) is a sampled drug level, N is a nonlinear autonomic function, and L is a linear operator that commonly is a convolution operation. The NL class of PD models includes the traditional effect compartment PD models as a subclass, but is not limited to such models. An algorithm and computer program named COLAPS, based on system analysis principles and hysteresis minimization, that enable N and L to be empirically determined for the NL class of models without addressing specific kinetic structure aspects ("model independence") are presented. The kinetic concepts of biophase conduction and transduction functions are used by COLAPS. Such an approach is more general than the effect compartment approaches because it does not assume first-order transport principles. The pitfalls of hysteresis minimization in PD modeling are discussed and the procedures taken by COLAPS to avoid these pitfalls are outlined. A transformation technique prevents improper convergence to a point. A novel reparameterization scheme is introduced that maximizes the flexibility of the kinetic functions and extends the generality of the analysis. Inequality function constraints are maintained without the need for troublesome constrained nonlinear optimization procedures. Usage of the COLAPS program is illustrated in the analysis of the PD of amobarbital. The COLAPS program resulted in an excellent minimization of the effect versus biophase level hysteresis. The biophase conduction function, the biophase drug level (normalized), and the transduction curve were determined. The transduction curve showed clear biphasic behavior.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1880731     DOI: 10.1002/jps.2600800518

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

Review 1.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

2.  Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions.

Authors:  J W Mandema; P Veng-Pedersen; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-12

3.  New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation.

Authors:  G Stagni; A M Shepherd; Y Liu; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1997-06

4.  The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.

Authors:  B Tuk; M Danhof; J W Mandema
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

Review 5.  Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Authors:  D D Breimer; M Danhof
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

6.  A 'bottom-up' approach for endo-PK/PD analysis.

Authors:  S Neelakantan; J A Widness; R L Schmidt; P Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2006-10       Impact factor: 1.627

Review 7.  Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives.

Authors:  M Danhof; J W Mandema; A Hoogerkamp; R A Mathôt
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

Review 8.  Pharmacokinetic and pharmacodynamic data and models in clinical trials.

Authors:  J L Steimer; M E Ebelin; J Van Bree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

9.  Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.

Authors:  M Gumbleton; S Oie; D Verotta
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

Review 10.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.